. 2019 Jan 1;10(2):494–503. doi: 10.7150/jca.26890

Table 1.

Correlation between the factors and clinicopathologic characteristics in ICC (Cohort 1, n=322)

Clinicopathological Indexes		LMR		P	CA19-9		P	SIS			P
Clinicopathological Indexes		low	high	P	low	high	P	I	II	III	P
Age(year)	≤50	23	62	0.000	57	28	0.782	23	40	22	0.953
Age(year)	>50	187	50	0.000	155	82	0.782	61	116	60	0.953
Sex	female	76	52	0.074	74	54	0.138	39	58	31	0.346
Sex	male	134	60	0.074	128	66	0.138	45	98	51	0.346
HBsAg	negative	135	64	0.21	125	74	0.146	49	88	62	0.011
HBsAg	positive	75	48	0.21	87	36	0.146	35	68	20	0.011
HCV	negative	209	111	1*	211	109	1*	84	155	81	0.746*
HCV	positive	1	1	1*	1	1	1*	0	1	1	0.746*
AFP (ng/ml)	≤20	186	100	0.846	188	98	0.911	84	128	74	0.000*
AFP (ng/ml)	>20	24	12	0.846	24	12	0.911	0	28	8	0.000*
Child-Pugh	A	202	109	0.753*	208	103	0.05*	83	151	77	0.183*
Child-Pugh	B or C	8	3	0.753*	4	7	0.05*	1	5	5	0.183*
Liver cirrhosis	no	156	80	0.581	149	87	0.090	58	113	65	0.317
Liver cirrhosis	yes	54	32	0.581	63	23	0.090	26	43	17	0.317
Tumor size (cm)	≤5	90	55	0.283	115	30	0.000	46	77	22	0.000
Tumor size (cm)	>5	120	57	0.283	97	80	0.000	38	79	60	0.000
Tumor number	single	163	81	0.291	164	80	0.358	72	110	62	0.033
Tumor number	multiple	47	31	0.291	48	30	0.358	12	46	20	0.033
Lymphonodus node metastasis	yes	41	15	0.167	25	31	0.000	5	29	22	0.001*
Lymphonodus node metastasis	no	169	97	0.167	187	79	0.000	79	127	60	0.001*
Microvascular invasion	yes	33	13	0.316	29	17	0.666	9	24	13	0.562
Microvascular invasion	no	177	99	0.316	183	93	0.666	75	132	69	0.562
Tumor differentiation^a	poor	46	22	0.903	49	19	0.207	17	37	14	0.249
	moderated	130	71		133	68		52	100	49
	well	34	19		30	23		15	19	19
TNM stage^b	I+II	155	93	0.061	178	70	0.000	75	121	52	0.000
TNM stage^b	III+IVA	55	19	0.061	34	40	0.000	9	35	30	0.000

Boldface type indicates significant values.

Abbreviations: AFP, alpha-fetoprotein; CA19-9, carbohydrate antigen 19-9; HBsAg, hepatitis B surface antigen; HCV, hepatitis C virus; LMR, lymphocyte-to-monocyte ratio; TNM, tumor-node-metastasis; SIS, combination of preoperative serum CA19-9 and LMR. I, CA19-9^Low/LMR^High; II, CA19-9^High/LMR^High and CA19-9^Low/LMR ^Low; III, CA19-9 ^High/LMR^Low.

^a Tumor differentiation was determined according to the “British Society of Gastroenterology guidelines on the management of cholangiocarcinoma”.

^b TNM stage: American Joint Committee on Cancer 7th edition staging for intrahepatic cholangiocarcinoma. *Fisher's exact tests; chi-square tests for all other analyses.